What to know
- Presentation Day/Time: Wednesday, April 23, 1:00–2:25 pm
- Presenter: Rebekah Sutter, MPH, BSN, RN, EIS officer assigned to the National Center for Emerging and Zoonotic Infectious Diseases, Division of Vector-Borne Diseases
What did we do?
- We described clinical characteristics of U.S. travelers with laboratory-confirmed oropouche virus (OROV) disease and assessed clinical criteria to improve case ascertainment and inform case definition development.
What did we find?
- As of November 22, 2024, 94 laboratory-confirmed OROV disease cases were identified among U.S. travelers, all with travel to Cuba.
- The median age was 52 years (range: 6-94 years); 52% were male.
- Common symptoms included fever, headache, myalgia, fatigue/malaise, chills, arthralgia, diarrhea, and nausea/vomiting.
- Severe manifestations included mucosal bleeding and neuroinvasive disease.
- Fourteen patients were hospitalized and 1 died, although attribution of death to OROV was uncertain.
- Case identification using different clinical criteria ranged from 71% to 99% with the optimal combination including fever or chills or ≥2 symptoms.
Why does it matter?
- OROV disease was identified among a wide age range of U.S. travelers during 2024.
- Disease presented most often as a self-limited febrile illness, although severe illness, including neuroinvasive disease, was reported.
- Optimizing clinical criteria for identifying suspect OROV disease cases will improve surveillance for this reemerging disease.
Abstract Category: Oropouche